Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fujirebio mesothelioma blood test:

This article was originally published in Clinica

Executive Summary

The US FDA has cleared for sale under its Humanitarian Device Exemption (HDE) programme what is claimed to be the first in vitro test for monitoring patients confirmed as having mesothelioma, a form of cancer linked to asbestos exposure. The Mesomark test, made by Fujirebio Diagnostics, enables doctors to more accurately detect disease recurrence and monitor treatment of patients, via a simple blood test, said the company, a subsidiary of Japan's Fujirebio. The company plans to collect more data to support the test's use for detecting mesothelioma. HDE approvals are intended to allow companies to show safety and probable benefit for products designed to treat a defined group of patients - fewer than 4,000 individuals in the US per year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT047567

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel